MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-15-2024
Brickell Biotech Operating Cycle 2011-2026 | BBI
Annual Operating Cycle Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 254 | 135 | 224 | 79.2 | 100 | 217 | - | 38.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 254 | 38.1 | 150 |
Quarterly Operating Cycle Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.8 | - | - | 1.12 K | 3.42 K | 170 | 398 | 118 | 144 | 137 | 122 | 98.7 | 118 | 75.8 | 78.9 | 60.9 | 82.7 | 99.3 | 80.5 | 79 | 111 | 84.6 | 163 | 133 | 271 | 288 | 195 | 84.7 | 90.3 | 125 | 21 | 148 | 10.7 | 349 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.42 K | 10.7 | 266 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.55 | -2.18 % | $ 1.06 B |  Canada |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
391 | $ 15.66 | -5.32 % | $ 3.73 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.16 | 1.51 % | $ 2.54 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
295 | $ 75.5 | -1.35 % | $ 1.46 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Corcept Therapeutics Incorporated
CORT
|
383 | $ 34.35 | -3.75 % | $ 3.57 B | USA |
 |
CorMedix
CRMD
|
127 | $ 6.32 | -11.24 % | $ 322 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
111 | - | - | $ 521 M | USA |
 |
Champions Oncology
CSBR
|
66.5 | $ 5.79 | -3.58 % | $ 79.1 M | USA |
 |
Axsome Therapeutics
AXSM
|
273 | $ 160.44 | -2.22 % | $ 7.98 B | USA |
 |
BridgeBio Pharma
BBIO
|
285 | $ 65.38 | -1.74 % | $ 12.5 B | USA |
 |
Denali Therapeutics
DNLI
|
1.89 | $ 19.69 | -3.34 % | $ 3.24 B | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Edesa Biotech
EDSA
|
97.1 | $ 3.8 | -10.9 % | $ 12.2 M | USA |
 |
Equillium
EQ
|
33.2 | $ 1.79 | 2.0 % | $ 62.2 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
349 | - | -7.31 % | $ 87 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 60.47 | 0.07 % | $ 11.6 B | USA |
 |
Eton Pharmaceuticals
ETON
|
55.7 | $ 17.04 | -2.77 % | $ 437 M | USA |